Centre Technology Transfer CITTRU

Staphylococcus pseudintermedius & bacteriocins – various applications

Posted by Centre Technology Transfer CITTRUResponsive · Patents for licensing · Poland

Summary of the technology

The subject of the present offer is new bacterial strain Staphylococcus pseudintermedius Sp222, isolated from dog pathologic dermal lesions.
The offer includes also peptide and protein bacteriocins produced by S. pseudintermedius Sp222. These bacteriocins exhibit a broad spectrum of biological activities:
- bacteriocin BacSp222 is able to kill a variety of Gram+ bacteria strains, including the methicillin resistant S. aureus (MRSA) strain. It is also cytotoxic towards selected eukaryotic cells and is resistant to action of proteolytic enzymes (either eukaryotic or prokaryotic) as well as to high temperature. The biological activity of BacSp222 is sustained even after limited fragmentation of its molecule by chemical reagents;
- lysostaphin Sp222 has an ability to effectively lyse (and, in consequence, to kill) the cells of Gram+ bacteria.

Centre Technology Transfer CITTRU

EN253_UJ_intermedius 222.pdf [PDF]

New and innovative aspects

Bacteriocins are an important group of molecules produced and secreted by multiple bacteria. These are ribosomally synthetized peptides or bacteria, capable of killing of strains closely related to the producer strain in low concentrations (nanomols /liter). This activity makes bacteriocins one of the main effectors, thanks to which the producer strain gains an advantage over the other microorganisms competing in the same ecological habitat or in the same physiological niche. Bacteriocins are also one of bacterial metabolic regulators dependent on producer cell population density as well as on presence of the other bacteria. Due to lack or relative lack of toxic effect on the vascular organisms, bacteriocins are safe in use and widely used as food and feed preservatives. Safety of bacteriocins use is primarily related to their commonness, in particular with commonness of the producing bacteria, present primarily in milk products, silages and meat products, which are the components of the human diet for thousands of years. Bacteriocin molecules are not antibiotics. Bacteriocins and antibiotics are two different groups of compounds. Antibiotics are the products of secondary metabolism of microorganisms, synthetized by enzymes other than ribosomes and of wide spectrum of effect, with the activity generally lower comparing to bacteriocins (the lethal effect of antibiotic requires usually the several magnitudes higher concentrations comparing to corresponding bacteriocins concentrations). As opposed to bacteriocins, application of antibiotics results in many side effects, harmful to humans, animals and environment, both in short- and long-term perspective. Application of antibiotics is limited primarily to medical and veterinary purposes and must be strictly controlled.

The new invention of the Jagiellonian University is providing a new bacterial strain Staphylococcus pseudintermedius Sp222, a new bacteriocin BacSp222 and a new lysostaphin Sp222.

Main advantages of its use

A comparison of bacteriocin BacSp222 and lysostaphin Sp222 with lytic and bactericidal properties, which are currently used in laboratory, revealed that:

  • bacteriocin BacSp222 is able to kill a variety of Gram+ bacteria strains, including the methicillin resistant S. aureus (MRSA) strain. It is also cytotoxic towards selected eukaryotic cells and is resistant to action of proteolytic enzymes (either eukaryotic or prokaryotic) as well as to high temperature. The biological activity of BacSp222 is sustained even after limited fragmentation of its molecule by chemical reagents;
  • lysostaphin Sp222 has an ability to effectively lyse (and, in consequence, to kill) the cells of Gram+ bacteria.

Specifications

The new bacterial strain according to the invention belongs to the Staphylococcus pseudintermedius species and is capable to produce peptide and protein bacteriocins of wide spectrum of biological effect: antibacterial or lytic to Gram-positive bacteria as well as cytotoxic or lytic to eukaryotic cells. In addition, the significant features of one of the bacteriocins produced by the said strain is high resistance of its molecule to decomposition by proteolytic enzymes, heat resistance and maintaining bioactivity upon partial molecule fragmentation by chemical agents.

In the other aspect, the invention concerns the new representative of lysostaphins of the working name lysostaphin Sp222, produced by the Sp222 bacterial strain according to the invention. The enzymatic sequence is new, however with statistically significant similarities to already known lysostaphins of the other bacteria. Also the activity of the new enzyme is similar. 

Applications

  • Both bacteriocins-producing strain Staphylococcus pseudintermedius Sp222 as well as bacteriocins have broad applications – mainly as food and animal feed preservatives. They are also used in medicine, pharmacy, veterinary medicine, cosmetology and natural science. Such broad purposes are primarily caused by the fact, that bacteriocins and bacteriocin-producing bacteria are generally recognized as safe and that they are widespread among such popular products as pickles, silages, dairy products and meats – constituents of human diet from many thousand years.

Intellectual property status

Bacterial strain Staphylococcus pseudintermedius Sp222 and its lytic and bactericidal proteins or peptides are the subject of patent application (PCT patent application – September 2015, priority date February 2015).

Current development status

Working prototype or samples ready for testing.

Desired business relationship

- commercial agreement

- licence aggreement

- technical cooperation – further development

- technical cooperation – adaptation to specific needs

Related keywords

  • Biology / Biotechnology
  • Microbiology Technology
  • Food Microbiology / Toxicology / Quality Control
  • Industrial Biotechnology
  • Veterinary Medicine
  • Medicine, Human Health
  • Pharmaceutical Products / Drugs
  • Microbiology Market
  • Agro and Marine biotech
  • Animal health
  • Food and feed ingredients
  • Food & feed ingredients
  • staphylococcus pseudintermedius
  • bacteriocin
  • lysostaphin
  • protein
  • peptide
  • laboratory reagents
  • Biotechnology
  • medicine
  • Pharmacy
  • veterinary medicine
  • cosmetology
  • natural science

About Centre Technology Transfer CITTRU

Technology Transfer Office from Poland

Centre for Innovation, Technology Transfer and University Development (CITTRU) is a part of Jagiellonian University, whose role is to promote university research, to support innovation and to create cooperation with the business. CITTRU main task is to offer the scientific achievements of the Jagiellonian University in the market by providing legal protection, licensing, sale of intellectual property rights, creation of academic business, coordination of company-ordered research projects, etc. Currently promoted technologies are mainly focused on new materials science, pharmacology and medical technology. Inventions offered by Jagiellonian University are promoted and awarded during numerous exhibitions, e.g. 58th International Exhibition of Innovation, Research and New Technologies INNOVA (BRUSSELS 2009), 38th International Exhibition of Invention New Techniques & Products (Geneva 2010) or 24th International exhibition of environmental equipment, technologies and services POLLUTEC (Paris 2009).

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.